Abstract：
BACKGROUND:Analyses suggest MDS patients with higher serum ferritin levels (SF) have inferior overall survival (OS), in one study across MDS subtypes. Multiple analyses suggest those with high SF receiving iron chelation therapy (ICT) have superior OS, but which MDS subtypes benefit from ICT remains undefined. METHODS:We performed survival analyses of MDS subtypes by receipt of ICT. RESULTS:182 MDS were lower IPSS risk and received red blood cell (RBC) transfusions; 63 received ICT. For the entire cohort, receiving ICT independently predicted superior OS in a multivariate analysis (hazard ratio for death 0.3, p=0.01). Features differing for ICT and non-ICT patients, respectively, were: age; IPSS risk group; number of RBC units transfused; and SF, p≤0.03 for all. At a median follow up of 76.5 and 28.4 months, 65.1% and 63.0% were alive. Median OS (months) for ICT and non-ICT patients was: RA, 140.9 and 36.3, p=0.0008; RARS/RARS-t, 133.4 and 73.3, p=0.02. For RCMD/RCMD-RS, p=NS, however, 3 (20%) had significant erythroid improvement with ICT; other subtypes had small numbers. DISCUSSION:In this retrospective analysis, RA and RARS/RARS-t patients receiving ICT had superior OS to non-ICT patients. These findings should be verified and other MDS subtypes examined in larger prospective analyses.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Wong SA,Leitch HAdoi
10.1016/j.leukres.2017.11.005subject
Has Abstractpub_date
2018-01-01 00:00:00pages
24-29eissn
0145-2126issn
1873-5835pii
S0145-2126(17)30583-0journal_volume
64pub_type
杂志文章abstract：BACKGROUND:Growing evidence demonstrates that an increased number of CD68 positive tumor-associated macrophages (TAM) is associated with decreased survival in patients with newly diagnosed classic Hodgkin lymphoma (HL). However, the impact of TAM in relapsed and refractory disease is unknown. DESIGN AND METHODS:To inv...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2013.03.021
更新日期：2013-09-01 00:00:00
abstract：:The technology of array comparative genomic hybridization (array-CGH/aCGH) enabled the identification of novel genomic aberrations in chronic lymphocytic leukemia (CLL) including the monoallelic and biallelic deletions affecting 22q11 locus. In contrast to previous publications, we hypothesized that the described 22q1...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2013.03.018
更新日期：2013-07-01 00:00:00
abstract：:The monoclonal antibody AGF2.3 identifies a nuclear envelope protein expressed at high levels in most transformed cell lines and weakly expressed in or absent from normal tissues and primary cell cultures. Here we report that expression of AGF2.3 antigen relates to the maturation status of cells. When HL60 cells were ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(86)90235-3
更新日期：1986-01-01 00:00:00
abstract：:AG-013736 is an oral anti-angiogenesis agent with activity against a variety of receptor tyrosine kinases, including VEGFR-1, VEGFR-2, VEGFR-3, c-kit, and PDGFR-beta. A phase 2 study was conducted in patients with poor prognosis AML or MDS. Twelve patients (six AML; six MDS) were treated with AG-013736 at a dose of 10...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2005.10.024
更新日期：2006-07-01 00:00:00
abstract：:Effects of the HDAC inhibitor LBH-589 (panobinostat) on fludarabine lethality toward acute myeloid leukemia (AML) cells were examined in vitro and in vivo. LBH-589 pretreatment sensitized U937, HL-60, and primary leukemia cells to fludarabine while blocking NF-κB activation accompanied by XIAP down-regulation and JNK ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2011.10.020
更新日期：2012-04-01 00:00:00
abstract：:Preclinical data suggest that all-trans retinoic acid (ATRA) synergizing with granulocyte colony stimulating factor (G-CSF), can improve the effectiveness of chemotherapy in acute myeloid leukemia (AML). Fludarabine 15 mg/m(2) is the minimum dose able to optimize intensification with fludarabine-arabinosylcytosine reg...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/j.leukres.2008.12.014
更新日期：2009-08-01 00:00:00
abstract：:Chlorambucil-induced apoptosis was assessed by three different flow cytometric methods in B-cell chronic lymphocytic leukaemia (B-CLL) cells cultured in vitro and the results were compared with those derived from the morphological assessment of the same samples. Spontaneous apoptosis was consistently observed in the c...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(98)00013-7
更新日期：1998-05-01 00:00:00
abstract：:Magnetic resonance provides a non-invasive tool for monitoring normal and leukemic bone marrow. Measurements of the T1 relaxation times are elevated in acute myelogenous leukemia. However, interpatient variability diminishes the usefulness of MR measurements for diagnosing leukemia. In following the time course of ind...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(88)90034-3
更新日期：1988-01-01 00:00:00
abstract：:Rearrangements in MLL (MLL-r) are common within very young children with leukemia and affect the prognosis and treatment. Previous studies have suggested the use of the NG2 molecule as a marker for MLL-r but these studies were performed using a small number of infants. We analyzed 148 patients (all less than 24 months...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2011.03.006
更新日期：2011-08-01 00:00:00
abstract：:Twenty-three patients with acute myelogenous leukemia (AML) in first relapse were treated with high-dose cytosine-arabinoside (Ara-C) and amsacrine or idarubicin. To prime the cells, the patients were given rhGM-CSF. We studied the influence of 48-h infusion of rhGM-CSF on proliferation and Ara-C sensitivity of leukem...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/0145-2126(96)00005-7
更新日期：1996-06-01 00:00:00
abstract：:Survivin is a newly discovered inhibitor of the apoptosis protein, IAP, expressed during development and in human cancers. The effector cell protease receptor-1 (EPR-1) gene is oriented in the opposite direction on the same DNA double strand. Thus, the Survivin and EPR-1 (Survivin/EPR-1) genes exist in a head-to-head ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(00)00065-5
更新日期：2000-11-01 00:00:00
abstract：:Chronic B-lymphocytic leukemia (B-CLL) cells may be regulated by immune functions. In an attempt to analyze such functions, helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8) and sIL-2R and beta 2-microglobulin were measured in serum of patients at different stages of the disease. Patient...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(92)90009-v
更新日期：1992-06-01 00:00:00
abstract：:Accumulation of cytosine arabinoside triphosphate (araCTP) from a range of cytosine arabinoside (araC) concentrations (1-50 microM) was measured during incubations of leukemic cells freshly isolated from patients with acute leukemia. In all but one patient, increments in extracellular araC above 10 microM did not incr...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(90)90035-8
更新日期：1990-01-01 00:00:00
abstract：:Multiple myeloma (MM) is an incurable plasma cell malignancy, which causes a significant morbidity due to organ damage and bone tissue destruction. In recent years, novel drugs have become available for MM therapy thanks to a more deepened knowledge of this disease's pathogenesis. The perspective of employing targeted...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/j.leukres.2012.10.016
更新日期：2013-02-01 00:00:00
abstract：:Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cases of CML in late C...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2008.10.024
更新日期：2009-05-01 00:00:00
abstract：:Multiple myeloma patients may develop extraosseous involvement in the course of the disease making prognosis very poor and new drugs clearly needed. The PD-1/PD-L1 axis has emerged as a master immune checkpoint in antitumor responses and recent studies investigated the role of PD-L1 in multiple myeloma cells; no data ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2016.09.008
更新日期：2016-10-01 00:00:00
abstract：:While critical steps in the regulation of leukemia cell development have been intensively studied in recent years, less is known about the interactions of leukemic cells with their stroma. Previously, we have shown that human acute myeloid leukemia (AML) cells differentiate upon injection into murine blastocysts. We h...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2007.09.014
更新日期：2008-05-01 00:00:00
abstract：:Proto-oncogene transcriptional activation was analyzed in a group of MCF 247 MuLv-induced T-cell lymphomas to identify transformation-specific gene activations and determine whether the proviral insertion near a myc gene could promote a peculiar mechanism of transformation through a differential proto-oncogene express...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(90)90007-v
更新日期：1990-01-01 00:00:00
abstract：:MEK/ERK signal pathway was required for the differentiation of granulocytes, megakaryocytes and erythrocytes. Recently, MEK/ERK cascade was reported to be involved in all-trans retinoic acid (ATRA) induced differentiation in acute promyelocytic leukemia (APL) cells. However, the upstream and downstream molecules of ME...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2016.03.008
更新日期：2016-06-01 00:00:00
abstract：:Thermal stress induces expression of a family of heat shock proteins which may regulate the synthesis of various cellular genes. We investigated the effect of heat shock on polyadenylation in Epstein-Barr Virus (EBV) negative and EBV transformed human Burkitt's lymphoma (BL) B-cell lines. Incubation of the BL B-cell l...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(95)00063-1
更新日期：1995-11-01 00:00:00
abstract：:Normal human monocytes express Fas and are susceptible to Fas ligand (FasL)-induced apoptosis. Because the myeloid leukemia cell lines HL-60 and THP-1 can be differentiated into functional monocytes and macrophages, we studied their expression of Fas and Fas ligand (FasL) to determine whether there were differentiatio...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(99)00101-0
更新日期：1999-10-01 00:00:00
abstract：:Standard chemotherapic approach for MZL is missing. We are presenting our monocenter experience with 2CdA+/-rituximab. Patients received 2CdA, 5mg/m(2), weekly, for 6 weeks. Patients receiving rituximab underwent to antibody administration in association with 2CdA, or after the end of chemotherapy. Global ORR was 89.3...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/j.leukres.2009.04.003
更新日期：2010-02-01 00:00:00
abstract：:A clonal origin of hematopoiesis was studied by investigation of X-chromosome inactivation patterns (XCIP) in isolated granulocyte, CD14(+) and CD3(+) subpopulations obtained from bone marrow and peripheral blood of 36 female patients with primary myelodysplastic syndrome (MDS). Clonality was assessed by PCR amplifica...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2004.08.008
更新日期：2005-04-01 00:00:00
abstract：:Radiotherapy (RT)is considered the treatment of choice in patients with Extra-nodal marginal zone lymphoma (EMZL) at early stage, but the presence of late toxicities has been limited the acceptance. Recently, low doses of RT LDR) (2 x 2 Gy) and the use of limited fields has been observed that retain the efficacy but e...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/j.leukres.2020.106443
更新日期：2020-11-01 00:00:00
abstract：:Fractionation of mononuclear cells from human fetal liver provides a cell population at early stages of myeloid differentiation which, when cultured, generates neutrophils and macrophages for up to a month. These studies describe the further purification of an undifferentiated myeloid blast cell population by rosette ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(90)90114-o
更新日期：1990-01-01 00:00:00
abstract：:Dequalinium (DQA) has been proposed as a selective antitumoral agent due to its preferential accumulation in mitochondria of cancer cells. Our aim was a better understanding of DQA cytotoxicity. DQA-induced NB4 and K562 cell alterations are initiated within the first 30 min of treatment at a high DQA concentration wit...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2006.11.018
更新日期：2007-07-01 00:00:00
abstract：:Human peripheral blood monocytes were found to be capable of phagocytizing human B-non Hodgkin's lymphoma (NHL) cells coated with mouse monoclonal antibodies (MoAbs). The MoAbs used recognized idiotypic determinants on the surface immunoglobulin (Ig) of the tumor cells. MoAbs of IgG1 and IgG2a subclass were equally ef...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(86)90344-9
更新日期：1986-01-01 00:00:00
abstract：:The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontinuation of IM. All 7 patients...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2012.02.011
更新日期：2012-06-01 00:00:00
abstract：:The goal of this study was to ascertain the specific effects of 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG) treatment in human acute myelogenous leukemia (AML). Four human leukemia cell lines were treated with varying doses of 17-AAG followed by analysis of toxicity, apoptosis, proliferation, and cell cycle. Cel...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2010.05.024
更新日期：2010-11-01 00:00:00
abstract：:We have recently described that a variant of L1210 leukemia cell (L1210/LN-1) originally fused with Lesch-Nyhan fibroblast is highly immunogenic for inducing tumor-specific transplantation immunity in (BALB/cxDBA/2)F1 mice. This finding has clearly been confirmed in the present study by in-vitro cell-mediated cytotoxi...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(85)90316-9
更新日期：1985-01-01 00:00:00
